Spotting the need to bridge scientific disciplines is one thing; building the bridge is quite another. Obtaining the necessary resources, breaking down existing boundaries, deconstructing stereotypes and convincing researchers to embrace a new 'bridging' discipline can all be highly challenging tasks. For instance, there has long been a consensus that there is a pressing need to fill the gap between basic sciences and clinical sciences to ensure effective application of the wealth of basic research discoveries of potential therapeutic relevance. But how exactly this could be best carried out is still the subject of much conversation and conjecture.
The challenges involved in bridging basic and clinical sciences were among the main issues discussed at a recent meeting at the University of Pennsylvania, co-sponsored by Nature Reviews Drug Discovery, entitled 'Translational Medicine and Therapeutics: The Future of Drug Development' . Most attendees at the meeting, whether from academia, industry, governments or regulatory agencies, agreed on two things. First, that bringing the two fields together is urgently needed to address many of the issues currently affecting R&D productivity; and second, that no one knows with any certainty how this can be achieved on a significant level.
The uncertainty about how to help this endeavour progress is well illustrated by one of the hottest topics of discussion at the meeting -what to call the discipline linking the basic and clinical sciences. Previous attempts have been less than successful: 'clinical pharmacology' never really got off the ground 1 , and although 'experimental medicine' saw a brief flicker of popularity in academic medical centres, it hasn't really flourished. The latest iteration -'translational medicine' -certainly encapsulates the concept of progress, but as yet does not seem to be sprinting off the blocks.
So, how important is it to establish a brand for this discipline? Well, the need to attract scientists to it is not just important for the discipline itself; it is good for drug discovery and development as a whole, given the necessity to stem the increasing loss of vital expertise in human pharmacology. Many leading figures associated with drug R&D have also spoken about the need to bring knowledge of disease earlier to the drug development process -for instance, in the development of biomarkers. Likewise, basic and clinical investigators are eager to see their discoveries make an impact on human health.
But at the moment, there are major obstacles hindering investigators from embracing translational medicine. In particular, adopting this discipline represents a cultural change in the way that academic departments are run and the relationships that they have with industry. The reward infrastructure isn't there to entice young, ambitious scientists to the area, and institutions still have much to learn about managing the conflict-of-interest issues that arise from the erosion of the traditional barriers between academia and industry.
Building a strong brand would help by creating a buzz, unifying communities and providing direction. This is particularly important because biomedical research as a whole seems to be going through a downturn in funding. In the United States, the halcyon days of successive budget doubling at the NIH between 1998-2003 seem to be over. The NIH budget is expected to decrease by 0.1% from last year, which is still a sizeable $28.6 billion, but represents the first true budgeted reduction in NIH support since 1970 2 . And after much disagreement over the size of the budget for the European Union's Seventh Framework Programme (FP7) for science and research within the 25 member states, a compromise was reached on a total budget of €48 billion ($58 billion) for 2007-2013, significantly down from the proposed €73 billion.
So, waiting to find the perfect banner under which to unite basic and clinical sciences might not be the most practical option. Trying to find a name that instantly fires the imagination and opens the pockets of funding bodies, like systems biology or nanotechnology, could be a distraction that is detrimental to getting vital funding. Agreeing on a name and sticking to it should create enough loyalty to the brand to provide a solid foundation on which to build enduring funding and growth. For it is worth repeating the consensus of opinion that there is a major need to address this gap. At the meeting, Mark Fishman, President of the Novartis Institutes for BioMedical Research, perhaps summed it up best, noting that someone must weave together the process from fundamental discovery to the clinic, and that given this, perhaps the physician-scientist is best placed to address the problems in drug discovery.
